Vascular and metabolic effects of the haem oxygenase-1 inducer haem arginate in subjects with the metabolic syndrome: A translational cross-over study

Diabetes and Vascular Disease Research

Volumn 13, Issue 1, 2016, Pages 41-48

  Dekker, Douwe ^a   Dorresteijn, Mirrin J ^a   Peters, Wilbert H M ^a   Bilos, Albert ^a   Pennings, Sebastiaan W C ^a   Wagener, Frank Adtg ^a   Smits, Paul ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

endothelial function; haem arginate; haem oxygenase; insulin resistance; metabolic syndrome; Translational medical research

Indexed keywords

ACETYLCHOLINE; ARGININE; CORTICOSTEROID; GLYCERYL TRINITRATE; HEME; HEME ARGINATE; HEME OXYGENASE 1; NONSTEROID ANTIINFLAMMATORY AGENT; BILIRUBIN; FERRITIN; MESSENGER RNA; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD VESSEL REACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; ECZEMA; ENZYME INDUCTION; FEMALE; FOREARM BLOOD FLOW; HEME BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VEIN OCCLUSION PLETHYSMOGRAPHY; DRUG EFFECTS; GENETICS; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZATION; VASODILATATION;

ACETYLCHOLINE; ADULT; AGED; ARGININE; BILIRUBIN; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FERRITINS; GLUCOSE CLAMP TECHNIQUE; HEME; HEME OXYGENASE-1; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITROGLYCERIN; RANDOM ALLOCATION; RNA, MESSENGER; TRANSLATIONAL MEDICAL RESEARCH; VASODILATION; VASODILATOR AGENTS;

EID: 84950326846     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115605047     Document Type: Article

References (33)

1. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 2003; 55: 551-571.
2. Abraham NG, Kappas A,. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79-127.
3. Lundberg AM, Hansson GK,. Innate immune signals in atherosclerosis. Clin Immunol 2010; 134: 5-24.
4. Osborn O, Olefsky JM,. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374.
5. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
6. Barbagallo I, Nicolosi A, Calabrese G, et al. The role of the heme oxygenase system in the metabolic syndrome. Curr Pharm Des 2014; 20: 4970-4974.
7. Burgess A, Li M, Vanella L, et al. Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice. Hypertension 2010; 56: 1124-1130.
8. Ndisang JF, Jadhav A,. Up-regulating the hemeoxygenase system enhances insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes in Goto-Kakizaki rats. Endocrinology 2009; 150: 2627-2636.
9. Ndisang JF, Jadhav A,. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes. Diabetes Obes Metab 2013; 15: 1029-1039.
10. Kawamura K, Ishikawa K, Wada Y, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol 2005; 25: 155-160.
11. Jais A, Einwallner E, Sharif O, et al. Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell 2014; 158: 25-40.
12. Bharucha AE, Kulkarni A, Choi KM, et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin Pharmacol Ther 2010; 87: 187-190.
13. Doberer D, Haschemi A, Andreas M, et al. Haem arginate infusion stimulates haem oxygenase-1 expression in healthy subjects. Br J Pharmacol 2010; 161: 1751-1762.
14. Andreas M, Schmid AI, Doberer D, et al. Heme arginate improves reperfusion patterns after ischemia: a randomized, placebo-controlled trial in healthy male subjects. J Cardiovasc Magn Reson 2012; 14: 55.
15. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
16. Benzie IF, Strain JJ,. The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power': the FRAP assay. Anal Biochem 1996; 239: 70-76.
17. Dekker D, Dorresteijn MJ, Pijnenburg M, et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011; 31: 458-463.
18. Liu D, Moberg E, Kollind M, et al. Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia. Diabetologia 1992; 35: 287-290.
19. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC,. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol Ther 2006; 111: 327-345.
20. Dong H, Huang H, Yun X, et al. Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology 2014; 155: 818-828.
21. Czibik G, Derumeaux G, Sawaki D, et al. Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology. Basic Res Cardiol 2014; 109: 450-464.
22. Ndisang JF, Lane N, Jadhav A,. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 2009; 150: 2098-2108.
23. Puy H, Gouya L, Deybach JC,. Porphyrias. Lancet 2010; 375: 924-937.
24. Dorresteijn MJ, Paine A, Zilian E, et al. Cell-type-specific downregulation of heme oxygenase-1 by lipopolysaccharide via Bach1 in primary human mononuclear cells. Free Radic Biol Med 2015; 78: 224-232.
25. Huang JY, Chiang MT, Chau LY,. Adipose overexpression of heme oxygenase-1 does not protect against high fat diet-induced insulin resistance in mice. PLoS ONE 2013; 8: e55369.
26. Munzel T, Daiber A, Gori T,. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011; 123: 2132-2144.
27. Agvald P, Adding LC, Gustafsson LE, et al. Nitric oxide generation, tachyphylaxis and cross-tachyphylaxis from nitrovasodilators in vivo. Eur J Pharmacol 1999; 385: 137-145.
28. Pae HO, Son Y, Kim NH, et al. Role of heme oxygenase in preserving vascular bioactive NO. Nitric Oxide 2010; 23: 251-257.
29. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 1383-1389.
30. Vinchi F, De Franceschi L, Ghigo A, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 2013; 127: 1317-1329.
31. Wagener FA, Eggert A, Boerman OC, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 2001; 98: 1802-1811.
32. Tokola O, Tenhunen R, Volin L, et al. Pharmacokinetics of intravenously administered haem arginate. Br J Clin Pharmacol 1986; 22: 331-335.
33. Juliano LM, Griffiths RR,. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology 2004; 176: 1-29.